![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder](https://mms.businesswire.com/media/20200921005170/en/819864/4/Interactive_Media_Placeholder_webready.jpg)
Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder
Teva Pharmaceuticals on Twitter: "View the highlights of our #Q1 contributions to #COVID19 efforts, keeping employees safe and ensuring medicines reach patients: https://t.co/AXGChhwZ8E $TEVA Forward-looking statements are subject to cautionary note in
![Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform | Business Wire Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform | Business Wire](https://mms.businesswire.com/media/20221114005344/en/739014/22/teva_RGB_JPEG.jpg)
Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform | Business Wire
![Teva Celebrates Pride with New Collection and a Donation to the It Gets Better Project | Deckers Brands Teva Celebrates Pride with New Collection and a Donation to the It Gets Better Project | Deckers Brands](https://mma.prnewswire.com/media/1169831/Sandals.jpg)
Teva Celebrates Pride with New Collection and a Donation to the It Gets Better Project | Deckers Brands
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg?download=1)